Reminder: Expert Access: Virtual Option Added (Tomorrow - 7AM EST/ 12PM BST): Barclays Hosted KOL Lunch at AAIC 2026: Diving into CELIA Data and Other Alzheimer’s Updates

Research evidence excerpt

Reminder: Expert Access: Virtual Option Added (Tomorrow - 7AM EST/ 12PM BST): Barclays Hosted KOL Lunch at AAIC 2026: Diving into CELIA Data and Other Alzheimer’s Updates

We will be attending the AAIC conference in person to be held in London starting Sunday,

July 12. Following the presentations over the weekend and after the full dataset of

Biogen's CELIA study on Tuesday afternoon, we'll be hosting Dr. Marc Gordon from

Northwell Health (US) for a lunch in central London to discuss key takeaways from CELIA

and all the data from the conference. We hope you can join us!

Guest Speaker

Dr. Marc Gordon, Chief of Neurology at Northwell Health's Zucker Hillside Hospital and

Professor of Neurology and Psychiatry at the Donald and Barbara Zucker School of

Medicine at Hofstra/Northwell

Barclays Host:

•• Emily Field, CFA, U.S. Biopharmaceuticals

Relevant Research:

•• Biogen Inc.: Oh CELIA...not quite breaking our hearts, but shaking our confidence

(maybe) (05/14/26)

•• Global Biopharma: Alzheimer's Disease KOL Call Prep Pack (06/11/26)

•• BIIB/LLY/BMY: Barclays Alzheimer's KOL Call: US takeaways (06/11/26)

•• CELIA full data: CDR-SB looks comparable to approved tx...justifying moving forward. So

why's the stock down so much? (07/14/26)

Meet the Speaker

Dr. Marc Gordon is the Chief of Neurology at Northwell Health's Zucker Hillside Hospital

and a Professor of Neurology and Psychiatry at the Donald and Barbara Zucker School of

Medicine at Hofstra/Northwell. Dr. Gordon's primary subspecialty interest is in behavioral

neurology and neuropsychiatry, and he treats 125 Alzheimer's patients annually. He has

been a principal investigator in clinical research studies of Alzheimer's disease, mild

cognitive impairment, and vascular dementia. His current research involves clinical trials